 Thomas Morrison
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chikungunya virus | 30 | 2024 | 63 | 11.530 |
Why?
| | Chikungunya Fever | 27 | 2024 | 63 | 9.460 |
Why?
| | Alphavirus Infections | 28 | 2022 | 42 | 9.210 |
Why?
| | Ross River virus | 18 | 2021 | 23 | 4.910 |
Why?
| | Viral Envelope Proteins | 11 | 2022 | 80 | 2.800 |
Why?
| | Interferon Type I | 9 | 2021 | 129 | 2.270 |
Why?
| | Host-Pathogen Interactions | 9 | 2021 | 300 | 2.220 |
Why?
| | Alphavirus | 9 | 2022 | 17 | 2.040 |
Why?
| | Virus Replication | 22 | 2022 | 405 | 1.840 |
Why?
| | Virulence Factors | 5 | 2018 | 140 | 1.640 |
Why?
| | Receptors, Immunologic | 3 | 2023 | 209 | 1.610 |
Why?
| | Lymph Nodes | 4 | 2024 | 455 | 1.550 |
Why?
| | Disease Models, Animal | 23 | 2022 | 3730 | 1.510 |
Why?
| | Antibodies, Viral | 15 | 2022 | 542 | 1.480 |
Why?
| | Adaptive Immunity | 5 | 2020 | 161 | 1.390 |
Why?
| | Animals | 83 | 2024 | 33381 | 1.390 |
Why?
| | Viral Proteins | 12 | 2019 | 296 | 1.370 |
Why?
| | Mice | 48 | 2023 | 15520 | 1.350 |
Why?
| | Viral Load | 11 | 2021 | 419 | 1.310 |
Why?
| | Newcastle disease virus | 13 | 2001 | 17 | 1.280 |
Why?
| | Antiviral Agents | 8 | 2021 | 654 | 1.260 |
Why?
| | Viruses | 4 | 2022 | 96 | 1.240 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 4 | 2021 | 4 | 1.230 |
Why?
| | Viral Vaccines | 4 | 2022 | 90 | 1.220 |
Why?
| | Mice, Inbred C57BL | 26 | 2021 | 4908 | 1.220 |
Why?
| | Arthritis | 4 | 2020 | 112 | 1.130 |
Why?
| | Arginase | 3 | 2015 | 29 | 1.110 |
Why?
| | Monocytes | 3 | 2020 | 513 | 1.110 |
Why?
| | Viremia | 3 | 2023 | 132 | 1.090 |
Why?
| | B-Lymphocytes | 4 | 2020 | 770 | 1.040 |
Why?
| | Antibodies, Neutralizing | 9 | 2023 | 228 | 1.010 |
Why?
| | Joints | 4 | 2020 | 85 | 0.970 |
Why?
| | Immunity, Innate | 7 | 2022 | 745 | 0.940 |
Why?
| | Interferon Regulatory Factors | 2 | 2022 | 31 | 0.930 |
Why?
| | RNA Virus Infections | 3 | 2019 | 11 | 0.920 |
Why?
| | Kupffer Cells | 2 | 2021 | 47 | 0.910 |
Why?
| | Virion | 3 | 2022 | 78 | 0.900 |
Why?
| | Virulence | 10 | 2021 | 240 | 0.900 |
Why?
| | Musculoskeletal Diseases | 2 | 2016 | 68 | 0.870 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2021 | 394 | 0.840 |
Why?
| | Inflammation | 9 | 2023 | 2566 | 0.840 |
Why?
| | Macrophages | 6 | 2022 | 1324 | 0.840 |
Why?
| | Mice, Knockout | 17 | 2022 | 2680 | 0.830 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 702 | 0.790 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2020 | 95 | 0.780 |
Why?
| | Neutrophils | 2 | 2020 | 1233 | 0.770 |
Why?
| | Viral Fusion Proteins | 8 | 2001 | 20 | 0.770 |
Why?
| | Capsid Proteins | 3 | 2020 | 70 | 0.760 |
Why?
| | RNA Viruses | 2 | 2019 | 28 | 0.760 |
Why?
| | Myositis | 3 | 2012 | 41 | 0.750 |
Why?
| | Viral Nonstructural Proteins | 3 | 2021 | 59 | 0.740 |
Why?
| | RNA, Viral | 13 | 2021 | 572 | 0.730 |
Why?
| | NADPH Oxidase 2 | 1 | 2020 | 42 | 0.730 |
Why?
| | Quinolones | 1 | 2021 | 98 | 0.730 |
Why?
| | O'nyong-nyong Virus | 1 | 2019 | 4 | 0.730 |
Why?
| | Complement System Proteins | 4 | 2023 | 294 | 0.730 |
Why?
| | Herpesvirus 4, Human | 4 | 2004 | 126 | 0.720 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2020 | 165 | 0.700 |
Why?
| | Leishmania major | 1 | 2018 | 6 | 0.680 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2018 | 7 | 0.680 |
Why?
| | Dendritic Cells | 2 | 2021 | 442 | 0.680 |
Why?
| | Myeloid Cells | 3 | 2015 | 128 | 0.660 |
Why?
| | Muscle, Skeletal | 9 | 2020 | 1515 | 0.640 |
Why?
| | Trans-Activators | 4 | 2004 | 373 | 0.630 |
Why?
| | Osteoarthritis | 1 | 2020 | 176 | 0.620 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2017 | 6 | 0.600 |
Why?
| | Chronic Disease | 4 | 2019 | 1636 | 0.580 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 339 | 0.580 |
Why?
| | Mutation, Missense | 2 | 2019 | 300 | 0.570 |
Why?
| | Zika Virus | 1 | 2017 | 61 | 0.570 |
Why?
| | Gene Deletion | 3 | 2018 | 361 | 0.560 |
Why?
| | Disease Outbreaks | 4 | 2023 | 322 | 0.560 |
Why?
| | Amino Acid Substitution | 3 | 2014 | 276 | 0.560 |
Why?
| | Zika Virus Infection | 1 | 2017 | 85 | 0.540 |
Why?
| | Immunization | 4 | 2024 | 412 | 0.530 |
Why?
| | Cell Line | 18 | 2021 | 2707 | 0.510 |
Why?
| | Complement Activation | 5 | 2018 | 350 | 0.510 |
Why?
| | Humans | 63 | 2023 | 118974 | 0.490 |
Why?
| | Tyrosine | 3 | 2013 | 233 | 0.460 |
Why?
| | Membrane Fusion | 3 | 2001 | 40 | 0.450 |
Why?
| | Histidine | 1 | 2013 | 63 | 0.450 |
Why?
| | Arthralgia | 1 | 2013 | 51 | 0.450 |
Why?
| | Endothelial Cells | 4 | 2024 | 732 | 0.450 |
Why?
| | Immunity, Cellular | 1 | 2014 | 270 | 0.440 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1346 | 0.420 |
Why?
| | Sindbis Virus | 4 | 2017 | 9 | 0.420 |
Why?
| | Severe Acute Respiratory Syndrome | 4 | 2018 | 14 | 0.410 |
Why?
| | Antibodies, Monoclonal | 4 | 2020 | 1284 | 0.390 |
Why?
| | Tenosynovitis | 1 | 2010 | 12 | 0.390 |
Why?
| | Emergency Responders | 2 | 2021 | 34 | 0.390 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2021 | 170 | 0.350 |
Why?
| | Vero Cells | 9 | 2021 | 69 | 0.350 |
Why?
| | Mice, Transgenic | 4 | 2021 | 2025 | 0.350 |
Why?
| | Up-Regulation | 1 | 2012 | 872 | 0.340 |
Why?
| | HN Protein | 3 | 1993 | 5 | 0.340 |
Why?
| | Lymphoid Tissue | 2 | 2019 | 65 | 0.340 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1774 | 0.340 |
Why?
| | Macrophage-1 Antigen | 1 | 2008 | 36 | 0.330 |
Why?
| | Virus Diseases | 1 | 2011 | 198 | 0.330 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 94 | 0.330 |
Why?
| | Arboviruses | 1 | 2008 | 9 | 0.320 |
Why?
| | Phenylalanine | 2 | 2022 | 66 | 0.320 |
Why?
| | Arbovirus Infections | 1 | 2008 | 18 | 0.310 |
Why?
| | Cricetinae | 6 | 2020 | 262 | 0.310 |
Why?
| | Cell Membrane | 4 | 2018 | 710 | 0.310 |
Why?
| | Complement C3 | 4 | 2018 | 192 | 0.310 |
Why?
| | Signal Transduction | 9 | 2021 | 4709 | 0.310 |
Why?
| | Adoptive Transfer | 2 | 2020 | 204 | 0.310 |
Why?
| | Adenoviridae | 2 | 2021 | 191 | 0.300 |
Why?
| | Mutagenesis, Site-Directed | 7 | 2010 | 363 | 0.300 |
Why?
| | Epitopes | 2 | 2020 | 443 | 0.300 |
Why?
| | West Nile virus | 2 | 2016 | 38 | 0.280 |
Why?
| | Phosphoproteins | 3 | 2016 | 308 | 0.280 |
Why?
| | Arthritis, Infectious | 1 | 2006 | 52 | 0.260 |
Why?
| | Cytokines | 5 | 2020 | 1900 | 0.260 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1206 | 0.250 |
Why?
| | Macaca mulatta | 2 | 2023 | 153 | 0.250 |
Why?
| | Down-Regulation | 2 | 2004 | 627 | 0.250 |
Why?
| | Immunoglobulin G | 4 | 2022 | 788 | 0.250 |
Why?
| | Immunoassay | 2 | 2021 | 101 | 0.240 |
Why?
| | Genome, Viral | 4 | 2019 | 124 | 0.240 |
Why?
| | Membrane Proteins | 2 | 2022 | 1055 | 0.240 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 28 | 0.240 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2004 | 147 | 0.230 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1067 | 0.220 |
Why?
| | Killer Cells, Natural | 3 | 2019 | 381 | 0.220 |
Why?
| | Antigens, Viral | 2 | 2021 | 181 | 0.220 |
Why?
| | Robotics | 1 | 2023 | 83 | 0.220 |
Why?
| | Arthritis, Rheumatoid | 1 | 2010 | 989 | 0.210 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 89 | 0.210 |
Why?
| | Salmonella | 1 | 2022 | 54 | 0.210 |
Why?
| | Protein Biosynthesis | 4 | 2019 | 397 | 0.210 |
Why?
| | Transcriptional Activation | 2 | 2022 | 348 | 0.210 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 114 | 0.200 |
Why?
| | NF-kappa B | 2 | 2008 | 670 | 0.200 |
Why?
| | Benzene Derivatives | 1 | 2021 | 13 | 0.200 |
Why?
| | Base Sequence | 9 | 2010 | 2159 | 0.200 |
Why?
| | Mice, Mutant Strains | 1 | 2021 | 280 | 0.200 |
Why?
| | Oligosaccharides | 1 | 2001 | 54 | 0.200 |
Why?
| | Horses | 1 | 2021 | 106 | 0.200 |
Why?
| | Convalescence | 1 | 2021 | 15 | 0.200 |
Why?
| | Interferon-gamma | 3 | 2010 | 736 | 0.190 |
Why?
| | Protein Domains | 1 | 2022 | 212 | 0.190 |
Why?
| | Gynecology | 1 | 2023 | 184 | 0.190 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 407 | 0.190 |
Why?
| | Cell Proliferation | 2 | 2018 | 2275 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2001 | 73 | 0.190 |
Why?
| | Specimen Handling | 1 | 2022 | 165 | 0.190 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 8 | 0.190 |
Why?
| | Oocytes | 2 | 2004 | 190 | 0.190 |
Why?
| | Influenza, Human | 2 | 2020 | 554 | 0.190 |
Why?
| | Culicidae | 2 | 2013 | 29 | 0.190 |
Why?
| | Lectins, C-Type | 1 | 2020 | 63 | 0.190 |
Why?
| | Type C Phospholipases | 1 | 2000 | 66 | 0.180 |
Why?
| | Interferon Regulatory Factor-3 | 2 | 2017 | 17 | 0.180 |
Why?
| | Xenopus | 1 | 2000 | 104 | 0.180 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2022 | 279 | 0.180 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2019 | 18 | 0.180 |
Why?
| | Glycoproteins | 2 | 2016 | 319 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 187 | 0.180 |
Why?
| | Encephalomyelitis, Venezuelan Equine | 1 | 2019 | 1 | 0.180 |
Why?
| | Mutation | 5 | 2021 | 3457 | 0.180 |
Why?
| | Benzylamines | 1 | 2019 | 40 | 0.180 |
Why?
| | STAT1 Transcription Factor | 2 | 2010 | 69 | 0.180 |
Why?
| | Blood Donors | 1 | 2021 | 109 | 0.180 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 46 | 0.180 |
Why?
| | Laparoscopy | 1 | 2023 | 417 | 0.170 |
Why?
| | Homeodomain Proteins | 3 | 2014 | 468 | 0.170 |
Why?
| | Primates | 2 | 2017 | 114 | 0.170 |
Why?
| | Blotting, Western | 3 | 2015 | 1194 | 0.170 |
Why?
| | Leishmania donovani | 1 | 2018 | 3 | 0.170 |
Why?
| | Parasite Load | 1 | 2018 | 8 | 0.170 |
Why?
| | Viral Tropism | 2 | 2019 | 24 | 0.170 |
Why?
| | Molecular Sequence Data | 7 | 2010 | 2871 | 0.170 |
Why?
| | Venules | 1 | 2018 | 13 | 0.170 |
Why?
| | Chemokine CCL21 | 1 | 2018 | 13 | 0.170 |
Why?
| | Lung | 5 | 2023 | 3664 | 0.170 |
Why?
| | Progesterone | 1 | 2000 | 242 | 0.170 |
Why?
| | Endothelium, Lymphatic | 1 | 2018 | 12 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1171 | 0.160 |
Why?
| | src-Family Kinases | 1 | 2019 | 90 | 0.160 |
Why?
| | Genes, Viral | 5 | 2006 | 93 | 0.160 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 984 | 0.160 |
Why?
| | Ovalbumin | 1 | 2018 | 165 | 0.160 |
Why?
| | Aedes | 2 | 2019 | 53 | 0.160 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 11 | 0.160 |
Why?
| | Stromal Cells | 1 | 2018 | 102 | 0.160 |
Why?
| | Female | 17 | 2021 | 61565 | 0.160 |
Why?
| | RNA, Messenger | 3 | 2019 | 2657 | 0.160 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.160 |
Why?
| | Hindlimb | 2 | 2010 | 137 | 0.160 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 30 | 0.160 |
Why?
| | Methotrexate | 1 | 2019 | 227 | 0.160 |
Why?
| | Diphtheria Toxin | 1 | 2017 | 63 | 0.150 |
Why?
| | Lysine | 1 | 2019 | 248 | 0.150 |
Why?
| | Polysaccharides | 1 | 2018 | 78 | 0.150 |
Why?
| | Protein Processing, Post-Translational | 4 | 2012 | 408 | 0.150 |
Why?
| | Gene Expression | 4 | 2015 | 1489 | 0.150 |
Why?
| | Transfection | 6 | 2009 | 888 | 0.150 |
Why?
| | HeLa Cells | 5 | 2023 | 583 | 0.150 |
Why?
| | Mutant Proteins | 2 | 2014 | 100 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 167 | 0.150 |
Why?
| | Mannose-Binding Lectin | 2 | 2018 | 21 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 254 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.140 |
Why?
| | Bacterial Proteins | 1 | 2022 | 759 | 0.140 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 46 | 0.140 |
Why?
| | Cytoplasm | 2 | 2017 | 269 | 0.140 |
Why?
| | Schistosomiasis mansoni | 1 | 2015 | 24 | 0.140 |
Why?
| | Schistosoma mansoni | 1 | 2015 | 39 | 0.140 |
Why?
| | alpha-Synuclein | 1 | 2015 | 29 | 0.140 |
Why?
| | Oxidative Stress | 1 | 2022 | 1178 | 0.130 |
Why?
| | Male | 11 | 2021 | 57801 | 0.130 |
Why?
| | RNA Caps | 1 | 2015 | 33 | 0.130 |
Why?
| | Histocompatibility Antigen H-2D | 1 | 2014 | 21 | 0.130 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 49 | 0.130 |
Why?
| | Vaccination | 2 | 2021 | 1222 | 0.130 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2015 | 35 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2015 | 72 | 0.130 |
Why?
| | Friend murine leukemia virus | 1 | 2015 | 30 | 0.130 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2015 | 112 | 0.130 |
Why?
| | Cytidine Deaminase | 1 | 2015 | 57 | 0.120 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2014 | 22 | 0.120 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 26 | 0.120 |
Why?
| | Animal Structures | 1 | 2014 | 8 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2015 | 1085 | 0.120 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2012 | 84 | 0.120 |
Why?
| | Glycosaminoglycans | 1 | 2013 | 78 | 0.120 |
Why?
| | Hospitalization | 1 | 2022 | 1785 | 0.110 |
Why?
| | Fibroblasts | 1 | 2018 | 842 | 0.110 |
Why?
| | Pandemics | 3 | 2023 | 1355 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 811 | 0.110 |
Why?
| | ELAV Proteins | 1 | 2012 | 17 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 381 | 0.110 |
Why?
| | Arthritis, Experimental | 1 | 2014 | 133 | 0.110 |
Why?
| | Mycobacterium tuberculosis | 1 | 2015 | 266 | 0.110 |
Why?
| | Amino Acids | 1 | 2016 | 465 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1012 | 0.110 |
Why?
| | Amino Acid Sequence | 6 | 1994 | 2071 | 0.110 |
Why?
| | Arthritis, Reactive | 1 | 2012 | 8 | 0.110 |
Why?
| | Carrier Proteins | 1 | 2016 | 726 | 0.110 |
Why?
| | Synovial Fluid | 2 | 2012 | 56 | 0.100 |
Why?
| | Structure-Activity Relationship | 3 | 2021 | 522 | 0.100 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 5 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1865 | 0.100 |
Why?
| | Newcastle Disease | 1 | 1990 | 1 | 0.100 |
Why?
| | Avian Leukosis Virus | 1 | 1990 | 7 | 0.100 |
Why?
| | Reassortant Viruses | 1 | 2010 | 7 | 0.100 |
Why?
| | Protective Agents | 1 | 2011 | 42 | 0.100 |
Why?
| | Transcription, Genetic | 3 | 2004 | 1323 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 146 | 0.100 |
Why?
| | Chickens | 1 | 1990 | 185 | 0.090 |
Why?
| | DNA, Viral | 5 | 1993 | 356 | 0.090 |
Why?
| | Receptors, Interferon | 1 | 2010 | 49 | 0.090 |
Why?
| | Immunotherapy | 1 | 2014 | 493 | 0.090 |
Why?
| | Genetic Vectors | 3 | 2021 | 302 | 0.090 |
Why?
| | COS Cells | 2 | 2001 | 184 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 16 | 0.090 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 140 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 35 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 79 | 0.090 |
Why?
| | Calgranulin B | 1 | 2008 | 6 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6412 | 0.080 |
Why?
| | Flavivirus Infections | 1 | 2008 | 9 | 0.080 |
Why?
| | Flavivirus | 1 | 2008 | 16 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 827 | 0.080 |
Why?
| | Cricetulus | 3 | 2014 | 98 | 0.080 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 80 | 0.080 |
Why?
| | Histocytochemistry | 1 | 2007 | 82 | 0.070 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1158 | 0.070 |
Why?
| | Insect Vectors | 1 | 2006 | 28 | 0.070 |
Why?
| | Serum | 1 | 2007 | 63 | 0.070 |
Why?
| | Cell Survival | 2 | 2021 | 1047 | 0.070 |
Why?
| | Mitochondrial Proteins | 1 | 2008 | 226 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.070 |
Why?
| | Glycosylation | 2 | 2006 | 129 | 0.070 |
Why?
| | Organ Specificity | 1 | 2006 | 278 | 0.070 |
Why?
| | Chick Embryo | 4 | 1992 | 129 | 0.060 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 52 | 0.060 |
Why?
| | Phosphorylation | 4 | 2012 | 1633 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 688 | 0.060 |
Why?
| | Genes, Immediate-Early | 1 | 2004 | 17 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 827 | 0.060 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 80 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2004 | 113 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2004 | 82 | 0.060 |
Why?
| | Plasmids | 3 | 1991 | 355 | 0.060 |
Why?
| | CHO Cells | 2 | 2014 | 143 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2004 | 55 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2019 | 625 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2004 | 175 | 0.060 |
Why?
| | Brain | 1 | 2015 | 2490 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2004 | 136 | 0.060 |
Why?
| | Centrifugation, Density Gradient | 2 | 2001 | 41 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2023 | 56 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 145 | 0.060 |
Why?
| | Culture Media, Conditioned | 1 | 2023 | 112 | 0.060 |
Why?
| | Cloning, Molecular | 3 | 2008 | 546 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2023 | 208 | 0.060 |
Why?
| | Binding Sites | 2 | 2021 | 1224 | 0.060 |
Why?
| | Bone and Bones | 1 | 2006 | 289 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 653 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2023 | 158 | 0.050 |
Why?
| | Body Weight | 1 | 2007 | 934 | 0.050 |
Why?
| | Keratinocytes | 1 | 2004 | 227 | 0.050 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2022 | 52 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2023 | 117 | 0.050 |
Why?
| | Mitochondria | 1 | 2008 | 786 | 0.050 |
Why?
| | Basal Ganglia Diseases | 1 | 2001 | 7 | 0.050 |
Why?
| | Australia | 1 | 2022 | 212 | 0.050 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2001 | 23 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1267 | 0.050 |
Why?
| | Cross Protection | 1 | 2021 | 4 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 107 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2004 | 580 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 116 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 20 | 0.050 |
Why?
| | Microsomes, Liver | 1 | 2021 | 59 | 0.050 |
Why?
| | Colorado | 2 | 2021 | 4196 | 0.050 |
Why?
| | Half-Life | 1 | 2021 | 147 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 130 | 0.050 |
Why?
| | Immunity | 1 | 2001 | 129 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 101 | 0.050 |
Why?
| | Tyrphostins | 1 | 2000 | 16 | 0.050 |
Why?
| | Phosphotyrosine | 1 | 2000 | 37 | 0.050 |
Why?
| | Giant Cells | 2 | 1998 | 22 | 0.050 |
Why?
| | Genetic Engineering | 1 | 2021 | 83 | 0.050 |
Why?
| | Metformin | 1 | 2004 | 295 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2674 | 0.050 |
Why?
| | Phosphoserine | 1 | 2000 | 34 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2022 | 253 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 410 | 0.050 |
Why?
| | Interleukin-1 | 1 | 2004 | 980 | 0.050 |
Why?
| | Kinetics | 2 | 2013 | 1624 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2000 | 147 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 576 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2019 | 139 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2015 | 4077 | 0.040 |
Why?
| | Mosquito Vectors | 1 | 2019 | 21 | 0.040 |
Why?
| | Protein Transport | 2 | 2012 | 412 | 0.040 |
Why?
| | Poly I-C | 1 | 2018 | 55 | 0.040 |
Why?
| | Interferon-beta | 2 | 2009 | 82 | 0.040 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2018 | 22 | 0.040 |
Why?
| | Trypsin | 1 | 1998 | 72 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2000 | 828 | 0.040 |
Why?
| | Autocrine Communication | 1 | 2018 | 42 | 0.040 |
Why?
| | Molecular Structure | 1 | 2019 | 459 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 122 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2018 | 48 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2018 | 57 | 0.040 |
Why?
| | Spleen | 1 | 2019 | 510 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 1032 | 0.040 |
Why?
| | Chemokines | 1 | 2018 | 230 | 0.040 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2016 | 9 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 341 | 0.040 |
Why?
| | Capsid | 1 | 2017 | 77 | 0.040 |
Why?
| | Biological Transport | 3 | 1992 | 382 | 0.040 |
Why?
| | Virus Assembly | 1 | 2017 | 67 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 37 | 0.040 |
Why?
| | Ouabain | 1 | 2016 | 15 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1795 | 0.040 |
Why?
| | Digoxin | 1 | 2016 | 27 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2009 | 564 | 0.040 |
Why?
| | Transcription Factors | 1 | 2004 | 1570 | 0.030 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 2 | 1985 | 4 | 0.030 |
Why?
| | Monensin | 2 | 1985 | 6 | 0.030 |
Why?
| | Drug Resistance, Viral | 1 | 2016 | 98 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 87 | 0.030 |
Why?
| | Viral Plaque Assay | 2 | 1992 | 24 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1945 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 177 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 969 | 0.030 |
Why?
| | Apoptosis | 1 | 2004 | 2484 | 0.030 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 1974 | 13 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 97 | 0.030 |
Why?
| | Reticulocytes | 1 | 1974 | 17 | 0.030 |
Why?
| | Virus Attachment | 1 | 2013 | 11 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2014 | 116 | 0.030 |
Why?
| | Calcium | 1 | 2000 | 1169 | 0.030 |
Why?
| | Heparitin Sulfate | 1 | 2013 | 42 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 41 | 0.030 |
Why?
| | Precipitin Tests | 1 | 1993 | 93 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2874 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2013 | 146 | 0.030 |
Why?
| | Static Electricity | 1 | 2013 | 121 | 0.030 |
Why?
| | Cell Fusion | 1 | 1993 | 51 | 0.030 |
Why?
| | Conserved Sequence | 1 | 1993 | 219 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2014 | 193 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 2851 | 0.030 |
Why?
| | Protein Binding | 2 | 2009 | 1975 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 139 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 310 | 0.030 |
Why?
| | Endosomes | 1 | 2013 | 128 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2013 | 161 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 565 | 0.030 |
Why?
| | Proteolysis | 1 | 2012 | 146 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 142 | 0.030 |
Why?
| | Viral Structural Proteins | 1 | 1991 | 12 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 269 | 0.020 |
Why?
| | Poultry | 1 | 1990 | 10 | 0.020 |
Why?
| | Complement C5a | 1 | 2011 | 60 | 0.020 |
Why?
| | Orthomyxoviridae | 1 | 1991 | 37 | 0.020 |
Why?
| | Tritium | 2 | 1985 | 70 | 0.020 |
Why?
| | Orthomyxoviridae Infections | 1 | 2011 | 53 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 332 | 0.020 |
Why?
| | Vaccines, Synthetic | 1 | 1990 | 128 | 0.020 |
Why?
| | Polyribosomes | 2 | 1984 | 23 | 0.020 |
Why?
| | Insulin | 1 | 2000 | 2162 | 0.020 |
Why?
| | DNA | 2 | 1988 | 1388 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 27617 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2001 | 3174 | 0.020 |
Why?
| | Chloramphenicol O-Acetyltransferase | 1 | 2009 | 37 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 311 | 0.020 |
Why?
| | Antibody Formation | 1 | 1990 | 276 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 76 | 0.020 |
Why?
| | Receptors, CCR | 1 | 2008 | 6 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 25 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 136 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 307 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1435 | 0.020 |
Why?
| | Seasons | 1 | 2011 | 461 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1882 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2009 | 140 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 403 | 0.020 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 34 | 0.020 |
Why?
| | Genes | 1 | 1988 | 231 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| | Neurons | 1 | 2015 | 1345 | 0.020 |
Why?
| | Protein Conformation | 2 | 1992 | 848 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 9000 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1986 | 42 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1986 | 193 | 0.020 |
Why?
| | Mercaptoethanol | 1 | 1985 | 12 | 0.020 |
Why?
| | Fucose | 1 | 1985 | 3 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2006 | 121 | 0.020 |
Why?
| | Disulfides | 1 | 1985 | 91 | 0.020 |
Why?
| | Immune System | 1 | 2006 | 181 | 0.020 |
Why?
| | Poly A | 1 | 1984 | 47 | 0.020 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 45 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 46 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2004 | 100 | 0.020 |
Why?
| | Response Elements | 1 | 2004 | 82 | 0.010 |
Why?
| | Xenopus laevis | 1 | 2004 | 128 | 0.010 |
Why?
| | Computational Biology | 1 | 2008 | 588 | 0.010 |
Why?
| | RNA | 1 | 2010 | 833 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1597 | 0.010 |
Why?
| | Models, Genetic | 1 | 2006 | 595 | 0.010 |
Why?
| | Adult | 2 | 2021 | 31512 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 823 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2001 | 44 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1308 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2445 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2004 | 1032 | 0.010 |
Why?
| | Carcinoma, Krebs 2 | 1 | 1974 | 1 | 0.010 |
Why?
| | Electrophoresis, Paper | 1 | 1974 | 1 | 0.010 |
Why?
| | Chromatography, Paper | 1 | 1974 | 3 | 0.010 |
Why?
| | Sulfur Radioisotopes | 1 | 1974 | 17 | 0.010 |
Why?
| | Hydroxyapatites | 1 | 1974 | 14 | 0.010 |
Why?
| | Chromatography | 1 | 1974 | 25 | 0.010 |
Why?
| | Tissue Extracts | 1 | 1974 | 20 | 0.010 |
Why?
| | Carbon Radioisotopes | 1 | 1974 | 45 | 0.010 |
Why?
| | Autoradiography | 1 | 1974 | 72 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1974 | 14 | 0.010 |
Why?
| | Cell-Free System | 1 | 1974 | 49 | 0.010 |
Why?
| | Triticum | 1 | 1974 | 11 | 0.010 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1974 | 38 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1992 | 62 | 0.010 |
Why?
| | Viral Matrix Proteins | 1 | 1992 | 24 | 0.010 |
Why?
| | Rabbits | 1 | 1974 | 780 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1992 | 336 | 0.010 |
Why?
|
|
Morrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|